Comparing Two Scan Schedules After Surgery for Retroperitoneal Sarcoma
Compares frequent versus less frequent imaging scans in adults after sarcoma surgery.
Plain-language title generated from the registry record
Registry title: High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma
Key facts
- Where
- Milan, ItalySee the site
- Phase
- Phase 3
Where in Italy
- Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Trial code
- NCT06480396
- Record updated
- 16 October 2024
- Original description
The SARveillance trial is an efficient, pragmatic, multi-centre, international, stratified, partially-randomised, patient-preference trial within a registry of high versus lower intensity radiological surveillance following primary resection of retroperitoneal, abdominal and pelvic soft tissue sarcoma. The trial design is stratified by sarcoma tumour grade (high/intermediate grade and low grade).Read full original descriptionShow less
An International, Partially-randomised, Patient-preference Trial Within a Registry of High Versus Lower Intensity Radiological Surveillance Following Primary Resection of Retroperitoneal, Abdominal and Pelvic Soft Tissue Sarcoma
The SARveillance trial is an efficient, pragmatic, multi-centre, international, stratified, partially-randomised, patient-preference trial within a registry of high versus lower intensity radiological surveillance following primary resection of retroperitoneal, abdominal and pelvic soft tissue sarcoma. The trial design is stratified by sarcoma tumour grade (high/intermediate grade and low grade).
Inclusion: Adult patients (greater than 18 years); Primary resection; Histologically confirmed retroperitoneal, abdominal or pelvic soft tissue sarcoma; R0/R1 resection; Eligible whether or not the participant undergoes neoadjuvant treatment.
Exclusion: Re-resection following previous inadequate surgery; R2 resection; Patients receiving adjuvant therapy that will delay, interrupt or render radiological surveillance unpredictable; Metastatic disease at time of randomisation; Recurrent, metastatic or residual disease identified on baseline CT imaging (3-4 months post primary resection); Uterine sarcomas, gastrointestinal stromal tumour (GIST), fibromatosis, epithelial tumours, multifocal disease, sarcomas of bony origin; Reoperation for recurrent soft tissue sarcoma; Patient declined to consent to data sharing with RESAR (unless in a centre contributing via pre-planned IPDMA).